# TG Therapeutics Sales Boost Raising Revenue Hopes

> TG Therapeutics' BRIUMVI sales surge lifts 2024 revenue outlook to $950m.
- Title: TG Therapeutics Sales Boost Raising Revenue Hopes | Shortify
- Summary: TG Therapeutics' BRIUMVI sales surge lifts 2024 revenue outlook to $950m. TG Therapeutics raised 2024 revenue guidance to $950 million after strong BRIUMVI…
- Keywords: tg therapeutics, briumvi, revenue guidance, 2024, msdos, nasdaq, investing, money, business, Therapeutics, Sales, Boost
- Source: Seekingalpha — https://seekingalpha.com/article/4957904-tg-therapeutics-the-business-is-more-attractive-than-the-valuation
- Author: High Alpha Professor
- Published: 2026-10-27T13:17:58+00:00
- Read time: 1 min
- Topics: tg therapeutics, briumvi, revenue guidance, 2024, msdos, nasdaq, investing, money, business
## BRIUMVI Sales Growth
BRIUMVI sales rose 15% to $227.7 million in Q2, up from $194.8 million in Q1.

> BRIUMVI, a multiple sclerosis drug developed and marketed by TG Therapeutics (TGTX), had US sales of $227.7 million in Q2, up from $194.8 million in Q1, a roughly 15% hike
## Revenue Guidance Raised
TG Therapeutics raised full-year revenue guidance to ~$950 million, approaching blockbuster status.

> Management raised full-year revenue guidance to ~$950 million, near blockbuster status
## Q3 Earnings Focus
Q3 earnings pivotal for margin improvement as net income fell due to elevated R&D and manufacturing expenses.

> Despite revenue momentum, net income fell sharply due to elevated R&D and manufacturing expenses, with Q3 earnings pivotal for margin improvement
## Key takeaway

TG Therapeutics raised 2024 revenue guidance to $950 million after strong BRIUMVI sales growth.